Scientists test Triple-Threat attack on tough blood cancers
NCT ID NCT03969446
Summary
This early-stage trial is testing a new combination of three drugs for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not responded to other treatments. The goal is to find the safest and most effective dose by combining an immunotherapy drug with two other cancer-fighting drugs. The study will enroll about 54 patients to closely monitor side effects and see if the treatment can put the cancer into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.